ramipril + valsartan + furosemide

This drug is a combination of three active pharmaceutical ingredients—ramipril, valsartan, and furosemide. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, valsartan is an angiotensin II receptor blocker (ARB), and furosemide is a loop diuretic. This combination would theoretically be used to manage hypertension and heart failure by targeting the renin-angiotensin-aldosterone system at multiple points while promoting diuresis to reduce fluid overload. Ramipril inhibits the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. Valsartan blocks the binding of angiotensin II to its receptor, further reducing vasoconstriction and aldosterone-mediated sodium retention. Furosemide acts on the ascending limb of the loop of Henle in the kidney to inhibit sodium and chloride reabsorption, resulting in increased urine output and decreased blood volume. While ACE inhibitors or ARBs are sometimes combined with diuretics like furosemide for synergistic effects in treating hypertension or heart failure[3][5], combining both an ACE inhibitor (ramipril) with an ARB (valsartan) plus a loop diuretic (furosemide) is not standard practice due to increased risk for adverse effects such as hypotension, renal dysfunction, hyperkalemia, and electrolyte imbalances[1][3][4][6]. Such combinations should only be considered under close medical supervision.

Other names

ramipril + valsartan + furosémideACEI + ARB + diuretic combination